Introduction {#S1}
============

Digestive cancers are a group of cancers that occur in the digestive tract, and include gastric cancer (GC), colorectal cancer, hepatocellular carcinoma, esophageal cancer, and pancreatic cancer. Digestive cancers accounted for around 26% of cancer cases and 35% of cancer deaths in the world in 2018 ([@B5]). Among them, the morbidity and mortality of GC in Eastern Asia is much higher than the worldwide average level. In China, the incidence of GC is only lower than lung cancer, and the mortality is third to lung cancer and liver cancer ([@B7]). Most patients suffering from early stage GC are asymptomatic and always develop distant metastasis at the time of diagnosis ([@B24]; [@B5]). Surgery is the main treatment for GC. Adjuvant or neoadjuvant therapy combined with surgery is commonly used to treat advanced GC, while targeted drugs for advanced GC, such as the HER2 (also known as ERBB2) antibody trastuzumab, and the VEGFR-2 antibody ramucirumab, are still in clinical trials ([@B24]). Therefore, developing biomarkers for the diagnosis, prognosis, and therapeutic response of digestive cancers, especially of GC, is necessary and urgent for reducing the mortality rate.

Mucins represent a group of glycoproteins encoded by MUC family genes. These high-molecular weight and filamentous glycoproteins could be classified into secreted mucins and membrane-bound mucins. In the digestive tract, secreted mucins form a mucus layer and act as part of a physical defensive barrier against external aggressive forces ([@B11]; [@B12]); membrane-bound mucins possess membrane specific domains which enable their diverse roles in signaling pathways ([@B11]; [@B12]). Not surprisingly, dysfunction of mucins in their fundamental roles is implicated in disease development at mucosal surfaces ([@B9]; [@B12]), and some mucins have been reported to display diagnostic or prognostic significance in different types of cancer. For example, MUC16, also known as CA125, is a widely used biomarker for the diagnosis of ovarian cancer ([@B27]; [@B15]) and was also found to be over-expressed in several other human malignancies, including pancreas, breast, and lung ([@B1]). MUC4 promotes carcinogenetic progression and has been proposed as a promising biomarker for pancreatic, ovarian, esophagus, and lung cancers ([@B16]; [@B15]). MUC15 overexpression is significantly correlated with several types of cancers, including colon cancer, hepatocellular carcinoma, and thyroid cancer ([@B14]; [@B18]; [@B25]; [@B8]). Moreover, *MUC4*/*MUC16*/*MUC20* high-expression signature was very recently reported to be correlated with poor overall survival (OS) in several types of digestive cancers including pancreatic, colon, and GCs ([@B15]). However, there are no systematic investigations, so far, on the association of MUC family members with diagnosis, prognosis, and/or therapeutic benefits, even though the Cancer Genome Atlas (TCGA) project is producing massive genomic, transcriptomic, proteomic, and clinical data involving more than 11,000 patients of 33 different types of tumors ([@B26]), and meanwhile, a number of web tools, such as GEPIA ([@B22]) and cBioPortal for Cancer Genomics ([@B6]; [@B13]), have been developed that enable users to easily and effectively mine TCGA data.

In the present study, by analyzing digestive cancer samples from TCGA involving colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), liver hepatocellular carcinoma (LIHC), stomach adenocarcinoma (STAD), and pancreatic adenocarcinoma (PAAD), we found that expression levels of *MUC15*, *MUC13*, and *MUC21* were individually associated with survival for all these digestive cancers, and high expressions of *EMCN* (MUC14) and *MUC15* were correlated with poor survival for STAD. Cox regression analysis showed that *EMCN*/*MUC15* combination still exhibited a significant correlation with the OS of GC patients. The prognostic prediction power of signature *EMCN*/*MUC15* was further validated on an independent GC dataset, GSE84437. *EMCN*/*MUC15* top 50 correlated genes were identified to be enriched in cancer-related processes, including vasculature development, mitosis, immunity, and so on. Taken together, we propose *EMCN*/*MUC15* combination as a potential prognostic signature for GC.

Materials and Methods {#S2}
=====================

Datasets {#S2.SS1}
--------

Datasets were collected from TCGA^[1](#footnote1){ref-type="fn"}^ and GEO^[2](#footnote2){ref-type="fn"}^ ([@B4]). Specifically, gene expression data (TPM, Transcripts Per Kilobase Million) and clinical data for digestive cancers including COAD, ESCA, LIHC, STAD, and PAAD, were analyzed with the online webserver GEPIA 1.0 ([@B22]). Among them, MUC family mRNA expression data (mRNA expression z-scores, which is based on RNASeqV2 processed and normalized using RSEM) and clinical profiles involving 407 STAD samples were extracted by using an online web tool cBioPortal for Cancer Genomics ([@B6]; [@B13]). Additionally, GSE84437 were extracted from the GEO database, which involves mRNA microarray data and clinical profiles of 433 GC samples.

Survival Analysis {#S2.SS2}
-----------------

Kaplan--Meier (KM) survival analysis for digestive cancer samples as a whole was carried out by using the webserver GEPIA 1.0 ([@B22]), and for GC samples (TCGA-STAD from cBioPortal and GSE84437 R package *survival*^[3](#footnote3){ref-type="fn"}^ was used. KM analysis was based on individual gene expression value and survival data. By using the median expression value of a query gene in a certain sample group as a cutoff, the samples were split into high and low expression groups with the expression level of the query gene not less than and less than the cutoff. The Cox proportional hazard model was built by using R package *survival*, fitted with two genes' expression values for OS or disease free survival (DFS). Similar to the individual gene analysis, the median value of weighted expression value (shortened as WEV) of a gene combination in a certain cohort were used as a group cutoff, where WEV was calculated as the sum of cox-regression coefficient weighted expression value of each gene involved in the combination. Log rank *p*-values, cox proportional hazard ratios (HRs), and HR *p*-values were calculated to compare the survival between two groups split by the median value of gene expression or WEV. A *p*-value of less than 0.05 and HR greater than 1.05 or less than 0.95 suggest statistical significance of the survival difference between high and low groups, which indicates the corresponding gene or gene combination has a prognostic potential.

Gene Co-expression Analysis and Enrichment Analysis {#S2.SS3}
---------------------------------------------------

Gene co-expression analysis was carried out using webserver cBioPortal, and the top 25 positively correlated and top 25 negatively correlated genes were selected according to Spearman correlation coefficients, which were taken together and simplified as "top 50 correlated genes" in our results. Here, correlated genes met two criteria: the absolute value of Spearman correlation coefficient is greater than 0.25, and the *p*-value is less than 0.01. Gene set enrichment analysis (GSEA) was performed by using R package *clusterProfiler* ([@B28]). The pathways enriched for GO (Gene Ontology) ([@B2]; [@B23]) were plotted based on the negative logarithm of *p*-value.

Results {#S3}
=======

MUC15, 13, and 21 Display Prognostic Potential for Digestive Cancer on TCGA {#S3.SS1}
---------------------------------------------------------------------------

Aiming to assess the prognostic potentials of every MUC gene, KM survival analysis was applied to TCGA digestive cancer samples as a whole involving COAD, ESCA, LIHC, STAD, and PAAD by using the webserver GEPIA 1.0 ([@B22]). Among the 14 MUC family members with expression data available, the expression levels of MUC1, MUC5AC, MUC6, OVGP1 (MUC9), MUC13, EMCN (MUC14), MUC15, MUC16, MUC17, and MUC21 individually exhibited significant correlations with OS, with HR *p*-values less than 0.05 and HR greater than 1.05 or less than 0.95; similarly, MUC2, MUC3A, MUC12, MUC13, MUC15, MUC17, MUC20, and MUC21 were significantly correlated with DFS ([Table 1](#T1){ref-type="table"} and [Supplementary Figure S1](#TS1){ref-type="supplementary-material"}). *MUC13*, *MUC15*, *MUC17*, and *MUC21* were significant for both OS and DFS, among which MUC15 performed best for OS correlation and the second best for DFS correlation. In comparison, MUC13 displayed the best performance in DFS analysis, while ranked relatively lower (9th) in OS analysis; MUC21 ranked 3rd for OS, and 8th for DFS ([Table 1](#T1){ref-type="table"} and [Supplementary Figure S1](#TS1){ref-type="supplementary-material"}). These indicate that *MUC15* represents a promising candidate for developing strategies for prognosis prediction for digestive cancers.

###### 

Survival analysis of TCGA digestive cancer samples for prognostic potentials of MUC family genes.

  **Gene**       **HR *p*-value for OS**   **OS *p*-value rank**   **HR *p*-value for DFS**   **DFS *p*-value rank**
  -------------- ------------------------- ----------------------- -------------------------- ------------------------
  MUC1           **1.3E−05**               6                       0.23                       11
  MUC2           0.69                      14                      **5.2E−08**                3
  MUC3A          0.49                      12                      **1.7E−06**                4
  MUC5AC         **7.9E−06**               5                       0.74                       14
  MUC6           **2.7E−07**               3                       0.41                       12
  OVGP1 (MUC9)   **0.0021**                7                       0.094                      10
  MUC12          0.58                      13                      **0.00012**                5
  MUC13          **0.032**                 9                       **2.1E−08**                1
  EMCN (MUC14)   **0.044**                 10                      0.71                       13
  MUC15          **1.7E−09**               1                       **3.6E−08**                2
  MUC16          **6.4E−09**               2                       0.059                      9
  MUC17          **0.0053**                8                       **0.00051**                6
  MUC20          0.36                      11                      **0.01**                   7
  MUC21          **9.8E−07**               4                       **0.01**                   8

OS stands for overall survival and DFS stands for disease free survival (DFS). The

p

-values less than 0.05 are displayed in bold.

MUC14 (EMCN) and 15 Display Prognostic Potential for Gastric Cancer on TCGA-STAD {#S3.SS2}
--------------------------------------------------------------------------------

To investigate the prognostic potentials of MUC family genes for STAD, we performed KM survival analysis exclusively on STAD samples from TCGA with R package *survival*. It was found that the expression levels of *EMCN* (MUC14) and *MUC15* individually showed significant correlations with both OS and DFS, and MCAM (MUC18) was significant only with OS ([Table 2](#T2){ref-type="table"}). KM survival plots, together with log rank *p*-values, cox proportional HRs, and HR *p*-values summarized in [Figure 1](#F1){ref-type="fig"} indicated that *EMCN* performed better than *MUC15* in both OS and DFS analyses. Overall, *EMCN* and *MUC15* could be potential biomarkers for STAD prognosis.

###### 

Survival analysis of TCGA STAD samples for prognostic potentials of MUC family genes.

  **Gene**       **HR *p*-value for OS**   **HR *p*-value for DFS**
  -------------- ------------------------- --------------------------
  MUC1           0.654                     0.591
  MUC2           0.129                     0.364
  MUC4           0.9                       0.203
  MUC5B          0.441                     0.753
  MUC6           0.67                      0.0854
  OVGP1 (MUC9)   0.662                     0.925
  MUC12          0.957                     0.637
  MUC13          0.0511                    0.234
  EMCN (MUC14)   **0.00154**               **0.00737**
  MUC15          **0.0185**                **0.0141**
  MUC16          0.825                     0.0975
  MUC17          0.145                     0.406
  MCAM (MUC18)   **0.0167**                0.323
  MUC20          0.891                     0.62
  MUC21          0.224                     0.745

OS stands for overall survival and DFS stands for disease free survival. The

p

-values less than 0.05 are displayed in bold.

![Survival analysis of TCGA STAD samples for prognostic potentials of EMCN (MUC14) and MUC15. **(A)** Overall Survival (OS) of EMCN. **(B)** Disease Free Survival (DFS) of EMCN. **(C)** Overall Survival of MUC15. **(D)** Disease Free Survival of MUC15. Log rank *p*-values, hazard ratios (HRs) and hazard ratio *p*-values were calculated. The 95% confidence intervals for survival time were shown in as dotted lines in the Kaplan--Meier (KM) survival plot.](fmolb-07-00019-g001){#F1}

*EMCN/MUC15* Combination Could Serve as Prognostic Signature for Gastric Cancer {#S3.SS3}
-------------------------------------------------------------------------------

So far we have observed that high expressions of both EMCN and MUC15 were associated with poor prognosis in GC, and that EMCN and MUC15 displayed the strongest correlation to survival for GC and digestive cancers, respectively ([Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). Thus, we set out to investigate whether *EMCN*/*MUC15* combination could be a prognostic signature for GC. Cox proportional hazards regression analysis was performed based on the two genes' expression values and OS data derived from TCGA STAD dataset. As expected, the expression of *EMCN*/*MUC15* combination exhibited significant correlation with OS, with log rank *p*-value of 0.00299 and HR *p*-value of 0.00301 ([Figure 2A](#F2){ref-type="fig"}).

![Overall survival analyses of gastric cancer (GC) samples from TCGA STAD **(A)** and GSE84437 **(B)** for predictive power of EMCN/MUC15 signature. Log rank *p*-values, hazard ratios (HRs) and hazard ratio *p*-values were calculated. The 95% confidence intervals for survival time were shown as dotted lines in the Kaplan--Meier survival plot.](fmolb-07-00019-g002){#F2}

We then separately tested the prognostic prediction power of *EMCN*, *MUC15* and their combination on an independent dataset, GSE84437, which involved 433 GC samples. Again, significant results of *EMCN*/*MUC15* combination (HR = 1.33) were obtained with log rank *p*-value being 0.0419 and HR *p*-value being 0.0413 ([Figure 2B](#F2){ref-type="fig"}); while one single gene, *EMCN* (HR *p*-value of 0.0807, HR = 1.27) or *MUC15* (HR *p*-value of 0.156, HR = 0.82), had no significant prognostic prediction power, as shown in [Supplementary Figure S2](#TS1){ref-type="supplementary-material"}. We therefore proposed that *EMCN*/*MUC15* combination could be a potential prognostic signature for GC.

*EMCN/MUC15* Correlated Genes Are Functionally Enriched in Cancer Related Processes {#S3.SS4}
-----------------------------------------------------------------------------------

By using webserver cBioPortal, the top 50 EMCN- ([Table 3](#T3){ref-type="table"}) or MUC15- ([Table 4](#T4){ref-type="table"}) correlated genes were identified based on mRNA expression data of TCGA STAD samples, including the top 25 positively correlated genes and top 25 negatively correlated genes. It is noticeable that there is no intersection between the two top 50 gene lists at all and no co-expression between *EMCN* and *MUC15* (Spearman's Correlation of 0.0264 with *p*-value of 0.592) either, implying the functional complementarity between *EMCN* and *MUC15* and thus the rationality of the combination of the two genes in predicting prognosis for GC.

###### 

Top 50 genes correlated with EMCN based on TCGA STAD dataset.

  **Correlated gene**   **Cytoband**   **Spearman correlation**   ***p*-value**
  --------------------- -------------- -------------------------- ---------------
  CYYR1                 21q21.3        0.931414                   2.19E−183
  MYCT1                 6q25.2         0.929044                   1.90E−180
  ERG                   21q22.2        0.894179                   3.19E−146
  DIPK2B                Xp11.3         0.887525                   4.57E−141
  ADGRL4                1p31.1         0.886757                   1.71E−140
  ***CD34***            1q32.2         0.880383                   6.99E−136
  ***TEK***             9p21.2         0.873397                   4.03E−131
  ***PECAM1***          17q23.3        0.871639                   5.73E−130
  S1PR1                 1p21.2         0.870224                   4.72E−129
  LDB2                  4p15.32        0.860092                   8.59E−123
  RHOJ                  14q23.2        0.859913                   1.10E−122
  CLEC14A               14q21.1        0.854201                   2.25E−119
  GNG11                 7q21.3         0.853027                   1.03E−118
  EBF1                  5q33.3         0.846286                   5.16E−115
  MMRN2                 10q23.2        0.846005                   7.29E−115
  CLEC1A                12p13.2        0.843416                   1.71E−113
  CALCRL                2q32.1         0.841594                   1.53E−112
  LRRC70                5q12.1         0.84015                    8.47E−112
  MEF2C                 5q14.3         0.839354                   2.16E−111
  ARHGEF15              17p13.1        0.836065                   9.86E−110
  CDH5                  16q21          0.828483                   4.80E−106
  PALMD                 1p21.2         0.828283                   5.97E−106
  SHE                   1q21.3         0.826792                   3.01E−105
  SPARCL1               4q22.1         0.823121                   1.52E−103
  JAM2                  21q21.3        0.821442                   8.85E−103
  RAD54L                1p34.1         --0.53926                  1.10E−32
  CDCA5                 11q13.1        --0.53612                  2.96E−32
  PKP3                  11p15.5        --0.53108                  1.41E−31
  CDCA8                 1p34.3         --0.5303                   1.79E−31
  ZWINT                 10q21.1        --0.52817                  3.44E−31
  KIF2C                 1p34.1         --0.52339                  1.46E−30
  HJURP                 2q37.1         --0.51982                  4.21E−30
  MCM2                  3q21.3         --0.51829                  6.63E−30
  CDT1                  16q24.3        --0.51369                  2.54E−29
  MYO19                 17q12          --0.51058                  6.24E−29
  TONSL                 8q24.3         --0.50684                  1.82E−28
  CCNA2                 4q27           --0.5056                   2.58E−28
  NCAPH                 2q11.2         --0.5018                   7.48E−28
  POC1A                 3p21.2         --0.50165                  7.81E−28
  NELFA                 4p16.3         --0.50116                  8.95E−28
  UBE2T                 1q32.1         --0.50026                  1.15E−27
  POLD2                 7p13           --0.49997                  1.25E−27
  DTL                   1q32.3         --0.49967                  1.35E−27
  PTBP1                 19p13.3        --0.49959                  1.38E−27
  CNOT11                2q11.2         --0.49871                  1.76E−27
  STIP1                 11q13.1        --0.49718                  2.69E−27
  MAP7                  6q23.3         --0.49631                  3.41E−27
  ESPL1                 12q13.13       --0.49591                  3.81E−27
  TBRG4                 7p13           --0.49548                  4.29E−27
  CDC25A                3p21.31        --0.49474                  5.24E−27

Genes mentioned in Discussion section are highlighted in bold and italic.

###### 

Top 50 genes correlated with MUC15 based on TCGA STAD dataset.

  **Correlated gene**   **Cytoband**    **Spearman correlation**   ***p*-value**
  --------------------- --------------- -------------------------- ---------------
  ANO3                  11p14.3-p14.2   0.558879                   1.82E−35
  FSTL4                 5q31.1          0.4959                     3.82E−27
  TMPRSS13              11q23.3         0.469609                   3.76E−24
  ZNF750                17q25.3         0.464898                   1.21E−23
  LGALS7                19q13.2         0.454428                   1.54E−22
  NCCRP1                19q13.2         0.452369                   2.52E−22
  PCLO                  7q21.11         0.449054                   5.50E−22
  GABRA3                Xq28            0.446711                   9.51E−22
  DLX3                  17q21.33        0.443637                   1.94E−21
  LIN28B                6q16.3-q21      0.440243                   4.21E−21
  ADGRV1                5q14.3          0.439028                   5.55E−21
  USH1G                 17q25.1         0.436641                   9.52E−21
  C12ORF56              12q14.2         0.429849                   4.32E−20
  RSPO4                 20p13           0.428819                   5.41E−20
  SPAG17                1p12            0.425992                   1.00E−19
  MARK1                 1q41            0.424353                   1.43E−19
  HTR2C                 Xq23            0.423044                   1.90E−19
  CT45A5                Xq26.3          0.420712                   3.13E−19
  PRPF40B               12q13.12        0.419994                   3.64E−19
  C3ORF67               3p14.2          0.419376                   4.16E−19
  RIPPLY3               21q22.13        0.417437                   6.27E−19
  CNGB3                 8q21.3          0.417398                   6.32E−19
  ATP6V0A4              7q34            0.413452                   1.45E−18
  LINC00964             8q24.13         0.412548                   1.74E−18
  VGLL1                 Xq26.3          0.409463                   3.30E−18
  MCUB                  4q25            --0.35985                  3.92E−14
  FAS                   10q23.31        --0.32779                  7.51E−12
  IRF1                  5q31.1          --0.32732                  8.08E−12
  ZIC2                  13q32.3         --0.31402                  5.99E−11
  CDC42SE2              5q31.1          --0.31243                  7.55E−11
  HK3                   5q35.2          --0.30198                  3.37E−10
  NUB1                  7q36.1          --0.30007                  4.41E−10
  GBP4                  1p22.2          --0.29733                  6.45E−10
  BBC3                  19q13.32        --0.29722                  6.55E−10
  AIM2                  1q23.1-q23.2    --0.29707                  6.68E−10
  NLRC5                 16q13           --0.29669                  7.04E−10
  MAX                   14q23.3         --0.29642                  7.30E−10
  MTHFD1                14q23.3         --0.29437                  9.67E−10
  AGAP2                 12q14.1         --0.29096                  1.54E−09
  ***IFNG***            12q15           --0.29068                  1.59E−09
  RASSF1                3p21.31         --0.28787                  2.32E−09
  GZMA                  5q11.2          --0.28696                  2.62E−09
  CCL4                  17q12           --0.28515                  3.32E−09
  MAT2B                 5q34            --0.28231                  4.82E−09
  FCGR3A                1q23.3          --0.28226                  4.85E−09
  THG1L                 5q33.3          --0.28207                  4.97E−09
  TK2                   16q21           --0.28202                  5.01E−09
  PRKX                  Xp22.33         --0.27772                  8.71E−09
  JAK2                  9p24.1          --0.27752                  8.94E−09
  EEF2                  19p13.3         --0.2774                   9.07E−09

Genes mentioned in Discussion section are highlighted in bold and italic.

We then performed functional enrichment analysis with the two top 50 correlated genes as a whole. GSEA identified a total of 22 GO terms ([Figure 3](#F3){ref-type="fig"} and [Supplementary Table S1](#TS1){ref-type="supplementary-material"}). Among them, the most significant pathways were associated with vasculature development, such as glomerulus vasculature development and renal system vasculature development. Some enriched pathways are associated with mitosis, such as mitotic sister chromatid segregation and mitotic metaphase plate congression. Some pathways were associated with immunity, such as inflammatory cell apoptotic process and response to interferon-gamma. The other enriched pathways were involved in DNA binding, cell cycle phase transition, cell polarity, phosphatase activity, and side of plasma membrane ([Figure 3](#F3){ref-type="fig"} and [Supplementary Table S1](#TS1){ref-type="supplementary-material"}). These indicate that genes correlated with EMCN and MUC15 in GC tend to be enriched in cancer related processes, such as vasculature development, mitosis, and immunity.

![Go terms derived from gene set enrichment analysis (GSEA) for top 50 EMCN- and MUC15-correlated genes. The pathways are ranked by -log *p*-value. The 95% confidence intervals for survival time were shown as dotted lines in the Kaplan--Meier survival plot.](fmolb-07-00019-g003){#F3}

Discussion {#S4}
==========

In the present study, by systematically analyzing mRNA expression and clinical data of TCGA digestive cancer samples and GEO GC samples, we propose MUC15 as a promising candidate for prognosis prediction of digestive cancers, and *EMCN*/*MUC15* combination as a potential prognostic signature for GC.

Gene signature identification is essentially a process of dimension reduction of high dimensional data. On one hand, a signature involving less features or genes obviously has more practicality; on the other hand, a signature is also expected to have sufficient interpretability, although it is far from achieved. In this sense, a good signature is supposed to consist of orthogonal or mutually exclusive features which are able to hold a testable hypothesis from a systematic viewpoint while also sustaining the robustness and reliability of the signature. However, most current efforts in this field focus on reducing dimension over enhancing explanatory power of the signature. In our work, although *EMCN* and *MUC15* coding genes belong to the same gene family, it is noted that there is no expression correlation between the two genes and no intersection between their top 50 correlated genes, implying the orthogonality and functional complementarity between EMCN and MUC15. As we expected, the combination of *EMCN*/*MUC15* shows more robust prognostic power than the individual genes in GC according to the testing result implemented on an independent dataset GSE84437. These observations not only support the rationality of the combination of the two genes in predicting prognosis, but also indicate the explanatory power of *EMCN*/*MUC15* signature, which is supposed to play an important role in the robustness improvement.

*EMCN*, i.e. MUC14, encodes a membrane-bound protein, endothelial sialomucin or mucin-like sialo glycoprotein, which was reported to inhibit cell and extracellular matrix interaction, interfere with leukocyte-endothelial cell adhesion, and even promote the peritoneal metastasis process of GC cells ([@B17]; [@B29]; [@B12]; [@B3]). Among the 22 enriched functions for top 50 EMCN-correlated genes and top 50 MUC15-correlated genes, the most significant one is glomerulus vasculature development that is associated with four *EMCN*/*MUC15* correlated genes including *CD34*, *TEK*, *PECAM1*, and *IFNG* ([Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"} and [Supplementary Table S1](#TS1){ref-type="supplementary-material"}). After carefully checking functional annotations of the four genes, we focused on two cancer relevant genes, *CD34* and *PECAM1*. Both genes are significantly coexpressed with *EMCN* with correlation coefficients of 0.880 and 0.871, respectively ([Table 3](#T3){ref-type="table"}). *CD34*, a marker of vascular endothelial cells, is capable of supporting cell adhesion by increasing surface expression ([@B19]). *PECAM1*, also known as *CD31*, encodes platelet endothelial cell adhesion molecule 1 that is necessary for leukocyte transendothelial migration (TEM) ([@B10]). It is noteworthy that *EMCN*/*COL4A5*/*CCL11* combination was very recently reported as a prognostic signature for diffuse type GC ([@B3]). In our study, among MUC family members, *EMCN* exhibits the strongest correlation with survival for GC. Taken together, *EMCN* may play crucial roles in tumorigenesis and progression of GC via cell adhesion and TEM of lymphocytes.

*MUC15* also encodes a membrane-bound protein, which could promote cell proliferation, cell-extracellular matrix adhesion, colony forming ability, and invasion in colon cancer cells ([@B14]). Its overexpression is significantly correlated with diverse cancers ([@B20]; [@B21]; [@B14]; [@B18]; [@B25]; [@B8]). However, it was also found that the expression of *MUC15* decreased in hepatocellular carcinoma cells and negatively regulated metastasis of hepatocellular carcinoma ([@B25]). This suggests that *MUC15* may perform diverse functions in tumorigenesis and progression. In our study, *MUC15* displays the strongest correlation among the MUC family with survival for digestive cancers and *MUC15* overexpression seems to be a promising candidate for a prognosis biomarker of digestive cancers. Combined with *EMCN*, the two genes provide a potential prognostic signature for GC and show more robustness in the prognostic prediction power than individual genes. As far as we know, the association of *MUC15* with GC is rarely reported.

In summary, we propose *EMCN*/*MUC15* combination as a prognostic signature with mechanistic interpretability. It not only possesses prognostic capability for GC, but also offers clues for further exploring systematic mechanisms of carcinogenesis of GC and other digestive cancers.
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